MDPI and ACS Style
Perri, F.; Longo, F.; Fusco, R.; D’Alessio, V.; Aversa, C.; Pavone, E.; Pontone, M.; Marciano, M.L.; Villano, S.; Franco, P.;
et al. Addendum: Perri et al. Electrochemotherapy as a First Line Treatment in Recurrent Squamous Cell Carcinoma of the Oral Cavity and Oropharynx PDL-1 Negative and/or with Evident Contraindication to Immunotherapy: A Randomized Multicenter Controlled Trial. Cancers 2021, 13, 2210. Cancers 2021, 13, 3412.
https://doi.org/10.3390/cancers13143412
AMA Style
Perri F, Longo F, Fusco R, D’Alessio V, Aversa C, Pavone E, Pontone M, Marciano ML, Villano S, Franco P,
et al. Addendum: Perri et al. Electrochemotherapy as a First Line Treatment in Recurrent Squamous Cell Carcinoma of the Oral Cavity and Oropharynx PDL-1 Negative and/or with Evident Contraindication to Immunotherapy: A Randomized Multicenter Controlled Trial. Cancers 2021, 13, 2210. Cancers. 2021; 13(14):3412.
https://doi.org/10.3390/cancers13143412
Chicago/Turabian Style
Perri, Francesco, Francesco Longo, Roberta Fusco, Valeria D’Alessio, Corrado Aversa, Ettore Pavone, Monica Pontone, Maria Luisa Marciano, Salvatore Villano, Pierluigi Franco,
and et al. 2021. "Addendum: Perri et al. Electrochemotherapy as a First Line Treatment in Recurrent Squamous Cell Carcinoma of the Oral Cavity and Oropharynx PDL-1 Negative and/or with Evident Contraindication to Immunotherapy: A Randomized Multicenter Controlled Trial. Cancers 2021, 13, 2210" Cancers 13, no. 14: 3412.
https://doi.org/10.3390/cancers13143412